Onegene Biotechnology’s UniStac platform is a post-translational fusion technology that can fuse two independently produced proteins into a single molecule with near 100% yield. Compared to existing DNA level fusion-based appraoches, it allows higher developability, efficacy and speed in developing multitarget protein drug.
UniStac’s Post-translational fusion method accelerates the development of multi-target therapeutics. The one of the most time-consuming step in the development of multi-target therapeutics is a discovery step, which requires a empirical combination of multiple APIs (Active Pharmaceutical Ingredients) to secure and evaluate as many different candidates as possible. UniStac quickly brings the best combination by conveniently combining and producing various ligands into the desired combination like Lego blocks.
Minimal Thermodynamic Penalty
UniStac is an enzyme-mediated conjugation which produces a branched conjugation linker or three-way structure. Therefore, newly added ligands always preserve free-end, which minimizes thermodynamic penalty and steric hindrance that is associated with protein conjugation to another protein. Furthermore, the UniStac scaffold which corresponds to the hinge region of the Fc-based platform is near 4 nm which is 10 times more spacious.
UniStac shows near 100% of conjugation yield under the mild conditions, which is pH 7 and at 25°C. The conjugation is site-specific, meaning only single amino acid on the whole protein surface is selectively used for the covalent bond formation. The superior conjugation yield or site-specificity is insensitive to the impurities, requiring only ~50% purity for the each protein to be conjugated. It is highly atom economic, which means the molar ratio of the two proteins for conjugation is near 1:1.